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Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of
relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated
blood from the pulmonary to the systemic circulation. More often, full term and near-term
infants are affected, however it is not uncommon to see PPHN in preterm infants who
have respiratory distress syndrome. In some infants pulmonary vascular remodeling is
present at birth, pointing toward the prenatal onset of the disease process. Regardless of
the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia
related short term and long-term morbidities. The mainstay therapy is the treatment of
the underlying condition along with several promising therapeutic modalities such as oxy-
gen supplementation, mechanical ventilation, nitric oxide, phosphodiesterase inhibitors,
prostaglandins analogs, endothelin receptor antagonists, and extracorporeal membrane
oxygenation. The optimal approach to the management of PPHN remains controversial.
After discharge from the NICU, infants with PPHN warrant long-term follow up since they
are at risk for neurodevelopmental disabilities and chronic health conditions.
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INTRODUCTION
Intra uterine relative hypoxemia, along with a multitude of other
factors is responsible for an elevated pulmonary vascular resistance
(PVR) that is almost twice as high in a fetus as in a newborn infant.
Soon after birth, there is an improvement in ventilation, oxygena-
tion, and pulmonary blood flow that lead to a decrease in PVR in
newborn infants. The neonatal PVR gradually decreases after birth
to reach the adult levels by 2 weeks of age (1). A failure of the post
natal reduction in PVR results in a serious medical condition called
Persistent Pulmonary Hypertension of the Newborn (PPHN).
Unless identified and treated promptly, PPHN is associated with
a significant morbidity and mortality that can be as high as 10–
20% (1). The pathogenesis of PPHN is multi-factorial including
maternal and neonatal causes; However Meconium Aspiration
Syndrome (MAS) remains the most common cause responsible
for PPHN (2). The introduction of Nitric Oxide (NO) as a thera-
peutic modality has revolutionized the management of PPHN and
successfully reduced the need for Extracorporeal Membrane Oxy-
genation (ECMO); however it did not reduce overall mortality in
these infants (3). This article reviews our current understanding
of the pathophysiology of PPHN, the current available therapeu-
tic modalities, and the short and long-term outcome of newborn
infants with PPHN.
METHODS
In January of 2013, EMBASE and PubMed databases were searched
using the key words persistent pulmonary hypertension, newborn,
inhaled NO, and ECMO. Cross-references of the relevant articles
were also searched for additional studies. No restrictions on lan-
guage or study designs were applied. Adult and pediatric clinical
studies as well as animal and bench research studies were reviewed
in preparation for this review. The quality of evidence of several
key clinical studies, included in this review, was graded accord-
ing to the American College of Chest Physicians (ACCPs) grading
guidelines which is a modified grading system of the international
GRADE group. The grading system classifies recommendations as
strong (Grade 1) or weak (Grade 2), and quality of evidence as high
(Grade A), moderate (Grade B), or low (Grade C) according to the
study design, the consistency of the results, and the directness of
the evidence (4).
FETAL CIRCULATION AND NEONATAL TRANSITION
The oxygenation of the human fetus is placenta dependent. Oxy-
genated blood is carried by the umbilical vein to the right atrium
and is preferentially carried to left atrium through the foramen
ovale. The portion of inferior vena cava distal to the diaphragm
receives the blood from ductus venosus, portal vein, right, and left
hepatic veins. A membranous valve called Eustachian valve pref-
erentially direct blood from most saturated ductus venosus to the
left atrium (5). The venous return from the superior vena cava and
inferior vena cava are mixed with the umbilical venous blood in the
right atrium and then enters to the right ventricle. The majority
of the right ventricular output is directed through the ductus arte-
riosus to the descending thoracic aorta, and only 13–25% of the
right ventricular output is directed to the pulmonary vasculature
(1). Therefore the saturation in the ascending aorta, descending
aorta, pulmonary artery, and vein are 65, 55, 55, and 45%, respec-
tively (1). As gestation advances, the weight indexed PVR increases.
Factors maintaining a high pulmonary vascular tone are multiple
including fetal lung fluid, low oxygen tension, and vasoactive fac-
tors such as endothelin-1 (ET1), platelet activating factor (PAF),
reactive oxygen species (ROS), and increased Rho A-Rho Kinase
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(RhoA-ROK) signaling (1). ET1 is the predominant ET in the pul-
monary vascular endothelial cells. Under hypoxic condition ET1
binds to its receptors ETA and ETB receptors. Stimulation of ETA
causes vasoconstriction by elevating intracellular Ca and stimula-
tion of ETB causes vasodilatation (1). The hypoxic fetal condition
also inhibits the production of vasodilator factors such as NO and
prostaglandins (PGs); Figure 1 (1, 6).
At birth with the first breath the lungs are filled with air and
there is an abrupt increase in pulmonary blood flow, creating a
shear stress with in the vessel wall. Shear stress and oxygenation
stimulate endothelial nitric oxide synthase (eNOS) and up regu-
late its expression. As a result NO is synthesized from l-Arginine
which then diffuses to the pulmonary smooth muscle cells and
activates soluble Guanylyl cyclase (sGC). Oxygenation up regu-
lates the expression and activity of sGC which converts GTP to
cGMP which further through the activity of cGMP dependent
protein kinase (PKG) cause smooth muscle relaxation. Oxygena-
tion also inhibits the enzymatic activity of phosphodiesterase 5
(PDE5) which converts cGMP to 5′ cGMP (1, 6).
Another pathway of pulmonary vasodilatation is through the
production of PG by the endothelium. The oxygenation is the
stimulus for the production of PG from the membrane arachi-
donic acid (AA) with cyclooxygenase (COX) as the rate limiting
enzyme. The predominant PG is PGI2 which stimulates adenylate
cyclase resulting in conversion of ATP to cAMP, causing relax-
ation of the pulmonary vasculature through cAMP dependent
protein kinase (PKA). Phosphodiesterase 3 (PDE3) enzyme con-
verts cAMP to AMP (1, 6). Overall the decrease in PVR caused by
PG is less than with NO (1).
In addition to NO and PGI2, potassium channel and calcium
channels are also involved in pulmonary vasodilatation. Oxygena-
tion results in pulmonary dilatation through the activation of
K channels and reduction in Ca channels in pulmonary artery
smooth muscles (1).
PATHOGENESIS
The PPHN is more common in late preterm and term babies.
The incidence of PPHN in term and late preterm is estimated to
be 1–2/1000 (2, 7). There are three main types of PPHN related
to under development, mal-development, and mal-adaptation
(7, 8). Some of the causes of PPHN related to underdevelop-
ment include congenital diaphragmatic hernia (CDH),pulmonary
hypoplasia, oligohydramnios from premature rupture of mem-
branes or renal agenesis, pleural effusion, vascular anomalies,
asphyxiating thoracic dystrophy, phrenic nerve agenesis, and alve-
olar capillary dysplasia (7). Some of the causes related to mal-
development include idiopathic or Primary PPHN, chronic fetal
hypoxia, fetal anemia, and premature closure of the ductus arte-
riosus (7). Some of the causes of PPHN related to mal-adaptation
include asphyxia, MAS, neonatal respiratory distress syndrome,
and sepsis/pneumonia (7). Congenital heart diseases such as total
anomalous pulmonary venous return, left atrial, or mitral obstruc-
tion, and hypoplastic left heart syndrome can be responsible for
PPHN. Polycythemia, hypoglycemia, and hypocalcemia can also
be responsible for PPHN. However MAS is the most common
cause of PPHN (2). Pulmonary hypertension in MAS results
from airway obstruction, inactivation of surfactant, and chemical
pneumonitis from the release of proinflammatory cytokines (9).
Pneumothorax, change of fetal heart beat pattern and asphyxia
are also risk factors for PPHN in MAS (10). The pulmonary
arteries in neonates with idiopathic PPHN are characterized by
the proliferation of smooth muscle cells of the normally muscle
free peripheral arteries. Animal studies have shown that hypoxia
result in decreased activity of matrix metalloproteinase-2 (MMP-
2) which is responsible for the deposition of collagen and elastin
in the arterial adventitia. As a result of smooth muscle prolifera-
tion and adventitial thickening the PVR increases to suprasystemic
levels causing right-to-left shunting through the ductus arte-
riosus and/or the foramen ovale. The resulting hypoxemia and
FIGURE 1 | Factors affecting the pulmonary vasculature tone. PAF, platelet activating factor; ET1, endothelin-1; ROS, reactive oxygen species; RhoA-ROK,
Rho A-Rho kinase; O2, oxygen; CO2, carbon dioxide; NO, nitric oxide; PG, prostaglandins.
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acidosis further aggravate the pulmonary vasoconstriction, creat-
ing a vicious cycle of right-to-left shunting, hypoxia, and acidosis
(1, 6, 11).
RISK FACTORS
Epidemiological studies have shown that the prevalence of PPHN
is increased in male infants, black or Asian maternal race, pre-
conception elevated body mass index (BMI> 27 vs. BMI< 20),
diabetes, asthma,cesarean section, late preterm,and large for gesta-
tional age (LGA); Table 1 (12, 13). Other risk factors have also been
described including histological chorioamnionitis and or funisi-
tis (14), and use of selective serotonin reuptake inhibitors (SSRIs)
(15, 16). In a fetal pulmonary artery Doppler velocity study, SSRI
exposure was found to increase slightly the right pulmonary arte-
rial blood flow during the third trimester; however not to the
extent of mounting PPHN (Grade 2C) (17). Another risk factor is
the antenatal exposure to non-steroidal anti-inflammatory drugs
(NSAIDs; Grade 2C) (18). Animal studies have shown that expo-
sure to PG inhibitors will lead to histological features similar to
PPHN (Grade 2C) (18). In one study, the use of NSAIDs dur-
ing pregnancy, particularly aspirin, ibuprofen, and naproxen were
found to be significantly associated with PPHN (19). However
in a large epidemiological study conducted in four metropoli-
tan areas (Boston, Philadelphia, San Diego, and Toronto) between
1998 and 2003 NSAIDs were not found to be associated with PPHN
(18). Group B Streptococcus (GBS) infection continues to be the
predominant cause of early onset sepsis. The Phosphatidylglyc-
erol and cardiolipin are the dominant phospholipids of GBS that
are associated with PPHN; and animal studies have shown that
indomethacin can lower the PVR induced by these agents (20).
There are case reports of ureaplasma infection causing PPHN
with a high case fatality rate, and Phospholipase A and C as the
incriminating agents (21). Following the introduction of thera-
peutic hypothermia for hypoxic ischemic encephalopathy there
was a concern whether cooling will aggravate PPHN. But none of
the studies have shown association of cooling with PPHN even
though some pulmonary dysfunction can happen in babies while
on cooling therapy (22, 23).
DIAGNOSIS
Persistent pulmonary hypertension of the newborn is suspected
clinically in term and near-term infants who have variable hemo-
globin oxygen saturation. A hyperoxia test, a quick bedside test,
can be performed to help making the diagnosis of PPHN. The
test consists of exposing infants to a Fraction of inspired Oxygen
(FiO2) of 100% for 5–10 min, and obtaining an arterial blood gas
(ABG). If the ABG shows that the partial arterial pressure of Oxy-
gen (PaO2) is<150 torr, the diagnosis of PPHN or a cyanotic heart
disease are suspected. To rule out a structural or congenital heart
disease, an echocardiogram is indicated. Among the various meth-
ods used to measure the pulmonary pressure, the pressure drop
across the PDA is a reliable method followed by the measurement
of TR (tricuspid regurgitation) jet velocity. However TR jet veloc-
ity has limitation in the presence of right ventricular dysfunction
which may be a feature of severe PPHN. In the absence of TR
jet, systolic ventricular septal flattening may be useful to diagnose
PPHN which indicate whether the right ventricular pressures are
Table 1 | Potential risk factors for the development of PPHN.
Male gender
African or Asian maternal race
Pre-conception maternal overweight
Maternal diabetes
Maternal asthma
Cesarean section
Late preterm and large for gestational age
Chorioamnionitis
Antenatal exposure to selective serotonin reuptake inhibitors
Antenatal exposure to non-steroidal anti-inflammatory drugs
Infection (mainly Group B Streptococcus)
Hypothermia
Hypocalcemia
Polycythemia
>half or <half of left ventricular systolic pressure. Echocardio-
graphic findings of impaired ejection fraction and stroke volume
carry a poor prognosis (24, 25). Imaging studies can be valuable
to make the diagnosis of PPHN, a chest X-ray can show oligemic
lung fields in primary PPHN and be helpful in diagnosing lung dis-
ease. A blood work up is helpful to identify the etiological factors
responsible for PPHN, a complete blood count can show abnor-
mal white blood cell counts and help rule out infections and can
show polycythemia. Blood glucose and calcium level are helpful
to rule out metabolic causes. An ECG is not usually helpful for the
diagnosis. Brain natriuretic peptide (BNP) is a reliable and eas-
ily available marker which contributes to the diagnosis of PPHN
especially if an echocardiogram is not readily available. Reynolds
et al. in a prospective cohort study have shown that an initial
BNP level of 550 pg/ml or greater was predictive of PPHN with a
sensitivity of 85% and a specificity of 100% (Grade 2C) (26). In
a prospective cohort study, Vijlbrief et al. have shown that BNP
level significantly increases in patients with rebound pulmonary
hypertension following the discontinuation of NO (27).
MANAGEMENT
The management of PPHN is to restore the cardiopulmonary
adaptation without inflicting an iatrogenic pulmonary injury
(Table 2). The management entails the treatment of the under-
lying etiology, maintenance of a normal systemic blood pressure,
and provision of an adequate tissue oxygenation.
The infant’s body temperature should be stabilized and han-
dling should be minimized to avoid stimulation and agitation of
the newborn infant. The use of sedatives is indicated especially
in infants who are mechanically ventilated to avoid agitation and
asynchrony with the ventilator support. The blood pressure should
be maintained with fluid resuscitation, pressors, and inotropes.
Antimicrobial therapy is indicated if infection is suspected.
Oxygen is a very important pulmonary vasodilator. If adequate
oxygenation cannot be attained by nasal cannula or hood oxy-
gen, infant should be ventilated. Hyperventilation used to be a
common practice to induce a respiratory alkalosis and therefore a
decrease in the PVR (28). But care should be taken to avoid venti-
lator induced lung injury as it can worsen the pulmonary arterial
www.frontiersin.org September 2013 | Volume 1 | Article 23 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Puthiyachirakkal and Mhanna Persistent pulmonary hypertension of the newborn
Table 2 |Treatment of PPHN.
Treatment of the underlying etiology
Mechanical ventilation
Surfactant
Nitric oxide (NO)
Phospho diesterase enzyme (PDE) inhibitors
• PDE5 inhibitor: sildenafil
• PDE3 inhibitor: milrinone
Prostaglandin analogs (PG)
• PGI2: iloprost
Magnesium sulfate
Endothelin receptor (ETR) antagonists
• ETR: bosentan
Extra corporeal membrane oxygenation (ECMO)
pressure (28). In addition, hyperventilation induced alkalosis that
can be responsible for shifting the oxygen hemoglobin dissocia-
tion curve to the left compromising oxygen delivery to the tissues.
There has been strong association between partial arterial carbon
dioxide (PaCO2) levels<25–30 mmHg and an increased incidence
of cystic periventricular leukomalacia (PVL) and cerebral palsy
(CP) in preterm and near-term infants (7). Therefore mechanical
ventilation should be targeting PaCO2 levels of 40–60 mmHg and
a PaO2 of 60–90 mmHg. High frequency oscillatory ventilation
(HFOV) can be attempted to minimize lung injury. However a
recent meta analysis have failed to show a clear benefit of HFOV
over conventional ventilation as an elective or as a rescue mode of
ventilation in term or preterm infants with PPHN (2, 7, 25). Dur-
ing ventilation and respiratory support, a special attention should
be taken to avoid hyperoxia; since hyperoxia has been shown to
cause a significant lung injury as it has been shown in multiple ani-
mal models and it can increase the development of peroxynitrite
in the presence of NO (1).
SURFACTANT
Surfactant therapy in neonates with PPHN has had variable results.
Surfactant did not improve lung compliance or duration to extu-
bation in infants with CDH treated with ECMO; however it
improved the severity of pulmonary morbidity, air leaks, and
length of hospital stay in infants with MAS and pneumonia (7).
In a multicenter randomized controlled study comparing surfac-
tant to placebo, surfactant use significantly decreased the need
for ECMO (Grade 1C) (7, 29). In another study, surfactant lung
lavage (SLL) showed an improvement in oxygenation, a decrease
in mean airway pressure (MAP), and A-a gradients, however it
did not improve the duration of mechanical ventilation, the use
of inhaled NO, length of hospitalization, or overall complications
(Grade 2A) (30).
NITRIC OXIDE
Several randomized controlled trials have demonstrated the effec-
tiveness of NO as a selective pulmonary vasodilator without many
side effects if used at proper concentration (Grade 1B) (3). NO
can be started in term or late preterm infants when the oxygen
index (OI) exceeds 25 or when the PaO2, while receiving 100%
FiO2, is <100 mmHg. In one of the early randomized controlled
study, the Neonatal Inhaled Nitric Oxide Study (NINOS), the most
effective dose of NO was 20 ppm. However few patients (6%)
who did not respond to 20 ppm responded to 80 ppm. A higher
concentration of NO is not without side effects. A high dose of
NO is associated with methemoglobinemia. In a recent trial, a
concentration of 80 ppm of NO was associated with methemo-
globinemia at a concentration of 7% and higher in 35% of the
time (31). In patients who do not respond to 20 ppm of NO, a
brief exposure to higher doses (40, 80 ppm) can be attempted,
however a rigorous monitoring of the concentration of methe-
moglobinemia should be undertaken. NO has been shown to
reduce the need for ECMO by 40% but it has not been able to
reduce mortality (Grade 1B) (3). Meta analysis of randomized
controlled trials of inhaled NO in term and near-term infants
did not show the beneficial effects of NO in patients with pul-
monary hypertension secondary to CDH (Grade 1B) (3). NO
seems to be equally effective in moderate or severe illnesses. In
premature babies with hypoxemic respiratory failure NO ther-
apy was shown to improve oxygenation without improvement in
survival; and it was associated with an increased risk for IVH
(Grade 1B) (3). Infants treated with NO may not respond to
the gas for multiple reasons, including the inability to deliver
NO to the pulmonary circulation secondary to poor lung infla-
tion, myocardial dysfunction, systemic hypotension, severe pul-
monary vascular structural disease, missed anatomic cardiovas-
cular lesions, such as total anomalous pulmonary venous return,
coarctation of the aorta, and alveolar capillary dysplasia (Grade
1B) (3, 32). A prospective cross-sectional online survey of neona-
tologists regarding the management of PPHN has shown that wide
variation exists on the threshold for initiation of iNO, dosage, and
weaning strategy. The most common initiating dose of iNO by
neonatologists is 20 ppm and 25% of neonatologist use more than
the maximum recommended dose of 20 ppm (33). The response
to NO is defined as an improvement in PaO2 or reduction in
FiO2 (33).
OTHER MEDICATIONS
Several medications have been used in the treatment of PPHN
including Phospho Diesterase Enzyme (PDE) inhibitors, PDE5
inhibitors, PDE3 inhibitors, Endothelin receptor (ETR) antago-
nists, PGs, Calcium channel blockers, magnesium sulfate, scav-
engers of ROS, and RhoA/Rho kinase inhibitors.
PDE5 INHIBITORS
Sildenafil is the only PDE5 inhibitor that is available for use in
newborn infants with PPHN. Sildenafil causes pulmonary vasodi-
latation by increasing the availability of cGMP. In a recent meta-
analysis sildenafil was shown to reduce mortality in newborn
infants where NO was not available (RR 0.20, 95% CI 0.07–0.57)
without clinically important side effects (Grade 2A) (34). In an
open-label, dose-escalation trial in newborns with PPHN contin-
uous IV infusion of sildenafil, acute, and sustained improvements
in oxygenation was noted (35). Sildenafil is associated with side
effects in infants. It can cause systemic hypotension and retinopa-
thy of prematurity in preterm infants. Kehat et al. in a case series
of 22 full terms and near-term infants did not find any ocular
complication related to sildenafil use (36).
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PDE3 INHIBITORS
Milrinone is a PDE3 inhibitor used for the treatment of PPHN
in infants. Milrinone increases the availability of cAMP causing
positive inotropic effect, peripheral vasodilatation, left ventricular
afterload reduction, and therefore increasing the cardiac output.
There are no randomized controlled studies assessing the efficacy
and safety of milrinone in infants with PPHN (37). More studies
are needed before routinely recommending milrinone in infants
with PPHN.
PROSTAGLANDIN ANALOGS
Intravenous PGs can cause both systemic and pulmonary vasodi-
latation. Randomized trials in adults and animal models have
shown its efficacy; however in neonates only case reports are avail-
able. Case reports have shown that inhaled/nebulized PGI2 and its
analogs iloprost can be helpful in newborn infants (38).
MAGNESIUM SULFATE
Animal studies have shown that intravenous magnesium sulfate
can cause reduction in pulmonary artery pressures (38). How-
ever in newborn infants, only observational studies are available
showing that magnesium sulfate can be helpful (38). The use
of magnesium sulfate should be limited especially that it can be
associated with systemic hypotension.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan is a non-selective ETR antagonist; Sitaxentan and
ambrisentan are selective ETA receptor inhibitors. Randomized
controlled studies and systematic reviews in adults have shown
improvement in outcomes of patients with pulmonary hyperten-
sion (38). Nakwan et al. have reported the benefits of bosentan in
neonates with PPHN (39). A recent randomized controlled trial
has shown its efficacy over placebo in a setting where NO was not
available (Grade 2B) (40).
EXTRACORPOREAL MEMBRANE OXYGENATION
Extracorporeal membrane oxygenation is the ultimate rescue ther-
apy for infants with PPHN with an oxygenation index persistently
>40 despite treatment with NO and optimal ventilator man-
agement. To be candidates for ECMO, infant should be >2 kg
in weight, and should have no contraindication to hepariniza-
tion such as severe IVH or non-survivable congenital anomalies.
Overall the survival of neonates with PPHN after ECMO ther-
apy is 80% and venoarterial ECMO is most often used for ease of
access (41). There are few predictors of good outcome in infants
with PPHN requiring ECMO. Higher birth weight, higher 5-min
Apgar score, absence of CDH, and postnatal diagnosis of CDH
are associated with an improvement in survival (41). The most
common complication of ECMO therapy is cardiovascular fol-
lowed by mechanical and renal. Neurodevelopmental disability
can be as common as 15–20% among ECMO survivors. The rate
of complications increases as the days on ECMO increases (41).
OUTCOME
The long-term outcome of infants with PPHN may depend on
their underlying conditions and the therapeutic interventions that
they have received at birth. The rate of neurodevelopmental dis-
abilities including cognitive delays and hearing deficit can be seen
in 6.4% of PPHN survivors (42). Feeding problems and short
term respiratory morbidities can be seen also in 24% of PPHN
survivors (42). Rosenberg et al. found no differences in medical,
neurodevelopmental, and social/emotional/behavioral outcomes
at school age, between children with PPHN who were treated with
iNO, with or without ECMO, and infants who were treated with-
out exposure to iNO (42). In a study at 18–24 months of age,
inhaled NO was not associated with an increase in neurodevelop-
mental, behavioral, or medical abnormalities in infants who were
treated for PPHN with or without iNO (43). In another long-
term follow up study, Eriksen et al. found that infants, who were
treated for PPHN at birth, had a higher prevalence of sensorineural
hearing loss, chronic health problems, need for bronchodilator
therapy, and remedial education at the age of 5–10 years in com-
parison to their controls (Grade 2C) (44). Long-term medical and
neurodevelopmental follow up of infants with PPHN is warranted.
CONCLUSION
Persistent pulmonary hypertension of the newborn is a neona-
tal emergency that requires early intervention and treatment to
prevent severe hypoxia and various short term and long-term
morbidities. The mainstay therapy is the treatment of the underly-
ing condition along with several promising therapeutic modalities
such as oxygen supplementation, mechanical ventilation, NO, PDE
inhibitors, PG analogs, ET receptor antagonists, and ECMO. How-
ever the optimal approach to the management of PPHN remains
controversial. Future high quality randomized controlled studies
of existent and new therapeutic modalities are needed to develop
strong, evidence based guidelines for the management of PPHN.
After discharge from the NICU, infants with PPHN warrant long-
term follow up since they are at risk for neurodevelopmental
disabilities and chronic health conditions.
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